246 related articles for article (PubMed ID: 35986103)
1. Neuropilin-2 promotes lineage plasticity and progression to neuroendocrine prostate cancer.
Wang J; Li J; Yin L; Pu T; Wei J; Karthikeyan V; Lin TP; Gao AC; Wu BJ
Oncogene; 2022 Sep; 41(37):4307-4317. PubMed ID: 35986103
[TBL] [Abstract][Full Text] [Related]
2. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
[TBL] [Abstract][Full Text] [Related]
3. A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network.
Lee AR; Gan Y; Tang Y; Dong X
EBioMedicine; 2018 Sep; 35():167-177. PubMed ID: 30100395
[TBL] [Abstract][Full Text] [Related]
4. Targeting RET Kinase in Neuroendocrine Prostate Cancer.
VanDeusen HR; Ramroop JR; Morel KL; Bae SY; Sheahan AV; Sychev Z; Lau NA; Cheng LC; Tan VM; Li Z; Petersen A; Lee JK; Park JW; Yang R; Hwang JH; Coleman I; Witte ON; Morrissey C; Corey E; Nelson PS; Ellis L; Drake JM
Mol Cancer Res; 2020 Aug; 18(8):1176-1188. PubMed ID: 32461304
[TBL] [Abstract][Full Text] [Related]
5. BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.
Kim DH; Sun D; Storck WK; Welker Leng K; Jenkins C; Coleman DJ; Sampson D; Guan X; Kumaraswamy A; Rodansky ES; Urrutia JA; Schwartzman JA; Zhang C; Beltran H; Labrecque MP; Morrissey C; Lucas JM; Coleman IM; Nelson PS; Corey E; Handelman SK; Sexton JZ; Aggarwal R; Abida W; Feng FY; Small EJ; Spratt DE; Bankhead A; Rao A; Gesner EM; Attwell S; Lakhotia S; Campeau E; Yates JA; Xia Z; Alumkal JJ
Clin Cancer Res; 2021 Sep; 27(17):4923-4936. PubMed ID: 34145028
[TBL] [Abstract][Full Text] [Related]
6. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
Nat Commun; 2020 Jan; 11(1):338. PubMed ID: 31953400
[TBL] [Abstract][Full Text] [Related]
7. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.
Bishop JL; Thaper D; Vahid S; Davies A; Ketola K; Kuruma H; Jama R; Nip KM; Angeles A; Johnson F; Wyatt AW; Fazli L; Gleave ME; Lin D; Rubin MA; Collins CC; Wang Y; Beltran H; Zoubeidi A
Cancer Discov; 2017 Jan; 7(1):54-71. PubMed ID: 27784708
[TBL] [Abstract][Full Text] [Related]
8. PAX6 promotes neuroendocrine phenotypes of prostate cancer via enhancing MET/STAT5A-mediated chromatin accessibility.
Jing N; Du X; Liang Y; Tao Z; Bao S; Xiao H; Dong B; Gao WQ; Fang YX
J Exp Clin Cancer Res; 2024 May; 43(1):144. PubMed ID: 38745318
[TBL] [Abstract][Full Text] [Related]
9. ONECUT2 is a driver of neuroendocrine prostate cancer.
Guo H; Ci X; Ahmed M; Hua JT; Soares F; Lin D; Puca L; Vosoughi A; Xue H; Li E; Su P; Chen S; Nguyen T; Liang Y; Zhang Y; Xu X; Xu J; Sheahan AV; Ba-Alawi W; Zhang S; Mahamud O; Vellanki RN; Gleave M; Bristow RG; Haibe-Kains B; Poirier JT; Rudin CM; Tsao MS; Wouters BG; Fazli L; Feng FY; Ellis L; van der Kwast T; Berlin A; Koritzinsky M; Boutros PC; Zoubeidi A; Beltran H; Wang Y; He HH
Nat Commun; 2019 Jan; 10(1):278. PubMed ID: 30655535
[TBL] [Abstract][Full Text] [Related]
10. SOX2 has dual functions as a regulator in the progression of neuroendocrine prostate cancer.
Li H; Wang L; Li Z; Geng X; Li M; Tang Q; Wu C; Lu Z
Lab Invest; 2020 Apr; 100(4):570-582. PubMed ID: 31772313
[TBL] [Abstract][Full Text] [Related]
11. LIN28B promotes the development of neuroendocrine prostate cancer.
Lovnicki J; Gan Y; Feng T; Li Y; Xie N; Ho CH; Lee AR; Chen X; Nappi L; Han B; Fazli L; Huang J; Gleave ME; Dong X
J Clin Invest; 2020 Oct; 130(10):5338-5348. PubMed ID: 32634132
[TBL] [Abstract][Full Text] [Related]
12. Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer.
Fernandes RC; Toubia J; Townley S; Hanson AR; Dredge BK; Pillman KA; Bert AG; Winter JM; Iggo R; Das R; Obinata D; ; Sandhu S; Risbridger GP; Taylor RA; Lawrence MG; Butler LM; Zoubeidi A; Gregory PA; Tilley WD; Hickey TE; Goodall GJ; Selth LA
Cell Rep; 2021 Jan; 34(1):108585. PubMed ID: 33406413
[TBL] [Abstract][Full Text] [Related]
13.
Bhagirath D; Yang TL; Tabatabai ZL; Majid S; Dahiya R; Tanaka Y; Saini S
Clin Cancer Res; 2019 Nov; 25(21):6532-6545. PubMed ID: 31371344
[TBL] [Abstract][Full Text] [Related]
14. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
[TBL] [Abstract][Full Text] [Related]
15. Selective Actionable and Druggable Protein Kinases Drive the Progression of Neuroendocrine Prostate Cancer.
Lu C; Qie Y; Liu S; Wu C; Zhang Z; Liu R; Yang K; Hu H; Xu Y
DNA Cell Biol; 2018 Sep; 37(9):758-766. PubMed ID: 29969286
[TBL] [Abstract][Full Text] [Related]
16. Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer.
Ci X; Hao J; Dong X; Choi SY; Xue H; Wu R; Qu S; Gout PW; Zhang F; Haegert AM; Fazli L; Crea F; Ong CJ; Zoubeidi A; He HH; Gleave ME; Collins CC; Lin D; Wang Y
Cancer Res; 2018 May; 78(10):2691-2704. PubMed ID: 29487201
[TBL] [Abstract][Full Text] [Related]
17. Molecular model for neuroendocrine prostate cancer progression.
Chen R; Dong X; Gleave M
BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Biological Features of Neuroendocrine Prostate Cancer.
Yamada Y; Beltran H
Curr Oncol Rep; 2021 Jan; 23(2):15. PubMed ID: 33433737
[TBL] [Abstract][Full Text] [Related]
19. The central role of Sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): A new targeted therapy of NEPC.
Lee CF; Chen YA; Hernandez E; Pong RC; Ma S; Hofstad M; Kapur P; Zhau H; Chung LW; Lai CH; Lin H; Lee MS; Raj GV; Hsieh JT
Clin Transl Med; 2022 Feb; 12(2):e695. PubMed ID: 35184376
[TBL] [Abstract][Full Text] [Related]
20. The β
Braadland PR; Ramberg H; Grytli HH; Urbanucci A; Nielsen HK; Guldvik IJ; Engedal A; Ketola K; Wang W; Svindland A; Mills IG; Bjartell A; Taskén KA
Mol Cancer Res; 2019 Nov; 17(11):2154-2168. PubMed ID: 31395667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
